Compare ELMT & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMT | PRME |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.9M | 553.2M |
| IPO Year | 2026 | 2022 |
| Metric | ELMT | PRME |
|---|---|---|
| Price | $20.17 | $3.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.56 |
| AVG Volume (30 Days) | 282.0K | ★ 2.6M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | N/A | $47.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $12.49 | $2.67 |
| 52 Week High | $20.91 | $6.94 |
| Indicator | ELMT | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 55.71 |
| Support Level | $13.96 | $3.16 |
| Resistance Level | N/A | $3.60 |
| Average True Range (ATR) | 1.34 | 0.21 |
| MACD | 0.37 | 0.05 |
| Stochastic Oscillator | 95.96 | 79.22 |
The Elmet Group Co provides precision-engineered components and high-energy systems for the Aerospace, Defense and Government, Industrial, Medical, Semiconductor and Electronics, and Energy industries. The company is organized into two business divisions, Critical Materials Components and Engineered Microwave Products, offering a platform with expertise across interconnected markets. The company operates an integrated engineering-to-production system, covering custom design, development, and processing across Critical Materials and High-Power Microwave. Its Engineered Microwave capabilities helps to deliver tailored microwave energy solutions, while its Critical Materials expertise allows to design reliable solutions for some of the demanding environments in the world.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.